Zimmer Biomet (NYSE:ZBH) Upgraded at Wells Fargo & Company

Zimmer Biomet (NYSE:ZBH – Get Free Report) was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a report released on Tuesday, FinViz reports. The firm presently has a $123.00 target price on the medical equipment provider’s stock, up from their previous target price of $113.00. Wells Fargo & Company‘s price target would suggest a potential upside of 21.18% from the stock’s current price.

Several other equities analysts have also commented on ZBH. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Monday. Sanford C. Bernstein upped their target price on shares of Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research report on Thursday, November 5th. Jefferies Financial Group restated a “hold” rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 4th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $114.32.

Read Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Stock Down 1.7%

Shares of ZBH opened at $101.50 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.79. The stock has a market capitalization of $19.21 billion, a price-to-earnings ratio of 25.70, a price-to-earnings-growth ratio of 2.45 and a beta of 0.50. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $112.54. The business’s 50 day simple moving average is $95.83 and its 200-day simple moving average is $92.64.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. During the same period last year, the firm posted $1.90 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, equities analysts expect that Zimmer Biomet will post 8.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several institutional investors have recently added to or reduced their stakes in ZBH. BlackRock Inc. bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $1,344,282,000. State Street Corp lifted its stake in shares of Zimmer Biomet by 0.6% during the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after acquiring an additional 52,044 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $328,578,000. Dimensional Fund Advisors LP boosted its holdings in Zimmer Biomet by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after acquiring an additional 24,208 shares during the period. Finally, Bank of America Corp DE purchased a new position in Zimmer Biomet during the 2nd quarter valued at $187,480,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

Featured Articles

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.